High SOX1 expression has been identified as a negative prognostic biomarker in cancer, with reduced SOX1 protein and/or mRNA levels correlating with poorer prognosis and shorter overall survival in ovarian cancer, hepatocellular carcinoma, and oesophageal squamous cell carcinoma [38, 39, 40]. This evidence concerns the gene SOX1 and cancer.